Jung Hun Koh

Jung Hun Koh

Auto-generated profile, based on publicly available information

Jung Hun Koh

Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
YYYeojin Yu
Yeojin Yu
KHKyungdo Han
Kyungdo Han
KLKyu-Na Lee
Kyu-Na Lee
JKJung Hun Koh
Jung Hun Koh
YSYoung Sun Shin
Young Sun Shin
SLSoojin Lee
Soojin Lee
Background: Obstructive sleep apnea (OSA) is a sleep disorder associated with an increased risk of cardiovascular and metabolic complications. Albuminuria, an early marker of kidney damage, is a proposed risk factor for OSA and its adverse outcomes. The study explored the association between OSA and albuminuria in Korean adults. Methods: We screened participants from the cross-sectional Korean National Health and Nutrition Examination Survey (2019– 2021). The study included participants aged 40 years and older who completed the STOP-BANG questionnaire, a tool used to assess the OSA risk. Albuminuria was defined as a urine albumin-to-creatinine ratio ≥30 mg/g Cr. The participants were categorized based on albuminuria presence and severity. A multivariate logistic regression analysis examined the association between albuminuria and OSA. Results: This study included 10,923 participants. Participants with albuminuria had significantly higher STOP-BANG scores than those without. Moreover, albuminuria remained strongly associated with an increased risk of OSA (odds ratio, 2.01; 95% confidence interval, 1.66–2.43), after multivariate adjustment. This association was more pronounced as albuminuria severity increased. Participants with high STOP-BANG scores were more likely to have albuminuria (odds ratio, 2.51; 95% confidence interval, 1.89–3.31), highlighting the bidirectional relationship between albuminuria and OSA. Conclusion: The present study demonstrated a significant association between albuminuria and an elevated risk of OSA. These findings underscore the importance of early screening for OSA in patients with albuminuria, particularly in those with additional metabolic risk factors, to improve their long-term outcomes.

1 December 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MKMinsang Kim
Minsang Kim
KHKyungdo Han
Kyungdo Han
JKJin Kyung Kwon
Jin Kyung Kwon
JOJae-Ik Oh
Jae-Ik Oh
JLJinsun Lee
Jinsun Lee
SPSehoon Park
Sehoon Park
Key Points: Lower bone mineral density was associated with a higher risk of fracture, irrespective of eGFR. At a similar bone mineral density, the fracture risk was higher with lower eGFR, more prominently for hip fractures than for vertebral fractures. The higher risk of fracture associated with lower eGFR was more pronounced in individuals with poor static balance. Background: Although both lower bone mineral density (BMD) and impaired kidney function are well-established risk factors for fracture, large-scale studies evaluating their effects and interaction on fracture, particularly site-specific fractures including vertebra and hip, are still limited. Methods: The main study population included female participants aged 66 years who underwent BMD assessment through dual-energy x-ray absorptiometry through the Korean National Screening Program between 2010 and 2016. BMD was categorized as normal, osteopenia, and osteoporosis on the basis of T -score. Kidney function was classified as eGFR ≥60, 45–59, and <45 ml/min per 1.73 m 2 . Primary outcome was any fracture, including vertebral, hip, and other fractures, defined using International Classification of Diseases, Tenth Revision codes. Subgroup analysis was performed by physical performance, including the single-leg stance test. Results: Among 551,548 participants included in the main study population, 80,514 developed any fracture over a median follow-up of 8.2 (interquartile range, 6.7–10.0) years. The prevalence of osteoporosis was 36%, and those with lower BMD showed higher eGFR and lower body mass index. Lower BMD was associated with a higher risk of any fracture, irrespective of eGFR, with nonsignificant interaction ( P for interaction = 0.54). Among participants with normal BMD, those with eGFR <45 ml/min per 1.73 m 2 showed a greater risk of hip fracture than those with normal eGFR (adjusted hazard ratio, 2.44 [1.88–3.18]), whereas vertebral fracture risks were similar across different eGFR categories at a given BMD status. Furthermore, a higher fracture risk with lower eGFR was more pronounced in women with poor static balance assessed by the single-leg stance test than in those with normal static balance. Conclusions: In postmenopausal women, lower BMD was associated with a higher fracture risk, irrespective of eGFR. However, at any given BMD, lower eGFR was associated with a greater risk for hip fracture, but not for vertebral fracture.

4 March 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
JOJae-Ik Oh
Jae-Ik Oh
KJKyeonghun Jeong
Kyeonghun Jeong
JKJung Hun Koh
Jung Hun Koh
JKJin Kyung Kwon
Jin Kyung Kwon
SCSemin Cho
Semin Cho
DKDong Ki Kim
Dong Ki Kim
Key Points: Plasma proteome profiling identified distinct signatures across biopsy-proven primary glomerular disease subtypes. An elastic net model using 93 proteins classified primary glomerular disease subtypes and controls, with external validation. Integrating proteomics with machine learning yields biologically interpretable insights in primary glomerular diseases. Background: Primary GN is a heterogeneous group of kidney disorders where understanding of their pathophysiology remains incomplete. Despite the diagnostic potential of high-throughput proteomics, constrained proteomic depth and a reliance on binary comparisons have left the feasibility of using systemic signatures to differentiate multiple GN subtypes largely unexplored. Methods: To identify protein signatures that noninvasively differentiate major primary glomerular disease subtypes and provide mechanistic insights, we performed large-scale systemic proteome profiling of 5416 plasma proteins via Olink Explore HT in a discovery cohort ( n =147) and an external validation cohort ( n =85) of Korean participants (mean age, 41±13 years; 46% female). The study population included patients with four GN subtypes—focal segmental glomerulosclerosis, IgA nephropathy, minimal change disease, and membranous nephropathy—alongside healthy controls. We developed a machine learning (ML) model using logistic regression with elastic net regularization to classify disease groups based on proteomic profiles and evaluated its performance in the independent validation cohort. Results: Plasma proteome profiles were distinct among disease subtypes, emerging as a significant source of data variation independent of conventional markers such as eGFR or proteinuria levels. The ML model performed robustly in both the discovery and validation cohorts, achieving an area under the receiver operating characteristic curve >0.8 for differentiating minimal change disease, membranous nephropathy, and IgA nephropathy. The model, even without clinical information, correctly identified 93% of minimal change disease cases (14 of 15) and 63% of IgA nephropathy cases (20 of 32), but its performance was limited for focal segmental glomerulosclerosis, with only 21% of cases (three of 14) correctly classified. Functional analysis of key proteins highlighted distinct biologic pathways, such as hemostasis in minimal change disease. Conclusions: We identified distinct systemic proteome signatures for primary glomerular diseases, where disease subtype served as a major determinant of proteomic variance alongside conventional clinical markers. ML models demonstrated robust discriminatory performance for minimal change disease, membranous nephropathy, and IgA nephropathy, underscoring the potential for proteome-based classification.

12 June 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
SPSehoon Park
Sehoon Park
MKMin Woo Kang
Min Woo Kang
JLJinsun Lee
Jinsun Lee
JOJaeik Oh
Jaeik Oh
MKMinsang Kim
Minsang Kim
DKDong Ki Kim
Dong Ki Kim
Background: Cardiovascular-Kidney-Metabolic (CKM) syndrome represents the progressive interplay among metabolic dysfunction, kidney impairment, and cardiovascular disease (CVD), ultimately contributing to higher mortality. We investigated how changes across CKM stages correlate with subsequent all-cause mortality in a nationwide population-based cohort. Methods: We analyzed data from 2,812,170 adults aged ≥20 years who underwent two general health screenings four years apart through the Korean National Health Insurance Service, with CKM stages classified according to clinical criteria reflecting progressive metabolic, kidney, and cardiovascular risk. Stage-specific CKM stage change (improve, sustain, or progress) and its association with all-cause mortality were evaluated using multivariable Cox regression analysis, adjusted for clinicodemographic variables. Results: During the four-year exposure assessment period, 674,465 adults (24%) experienced CKM stage progress, 1,802,489 (64%) sustained their CKM stage, and 335,216 (12%) improved. Over a subsequent 6.4-year follow-up, CKM stage progress was significantly associated with an higher risk of all-cause mortality [adjusted HR 1.38 (1.36–1.41)], whereas CKM stage improvement was associated with a lower risk [adjusted HR 0.93 (0.90–0.95)]. Notably, even early-stage progression (from stage 0 to stage 1) was linked to a higher mortality risk [adjusted HR 1.08 (1.01–1.15)], with a stepwise higher risk observed with progression to more advanced follow-up CKM stages. The association between CKM stage progress and mortality was more pronounced in older adults. Conclusion: Worsening of CKM stage is associated with higher all-cause mortality from early to advanced stages, whereas CKM stage improvement is associated with lower mortality risk. These findings provide epidemiologic real-world evidence supporting the importance of monitoring and intervening on CKM progression across its full spectrum to lower long-term mortality risk.

1 January 2026 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JKJung Hun Koh
Jung Hun Koh
YHYoujin Hong
Youjin Hong
ESEun Ji Sim
Eun Ji Sim
SSSoseul Sung
Soseul Sung
WLWoojin Lim
Woojin Lim
KSKorean Breast Cancer Society
Korean Breast Cancer Society
Koh JH, et al. J Breast Cancer. 2026 Aug;29(4):389-394. https://doi.org/10.4048/jbc.2025.0109

25 July 2026 in American Journal of Transplantation
Verified
Journal Article
Closed access
JKJi Eun Kim
Ji Eun Kim
HCHyunjeong Cho
Hyunjeong Cho
JLJangwook Lee
Jangwook Lee
JPJi In Park
Ji In Park
JKJung Hun Koh
Jung Hun Koh
HLHajeong Lee
Hajeong Lee